fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      50   |   51   |   52   |   53   |   54   |   55   |   56   |   57   |   58   |   59   |   60      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2007-06-14 Develogen (Germany)/Andromeda Biotech (Israel)
 
DiaPep277® (peptide immunomodulator) / type 1 diabetes commercialization/ distribution
development
See details
2007-06-05 DSM Biologics/Crucell (The Netherlands)/Sartorius Biotech (Germany)
 
PER.C6® technology /   licensing
See details
2007-06-04 Cancer Research Technology (GB) and the University of Manchester
AstraZeneca
biomarkers / cancer R&D
See details
2007-05-31 ProBioGen (Germany)
Virbac (France)
AGE1 avian cell lines /   licensing
See details
2007-05-30 Vivalis (France)
Nobilon (The Netherlands)
EBx® cell lines / human influenza vaccines /   licensing
See details
2007-05-30 Intercell (Austria)/Bachem (Switzerland)
 
peptide KLK /   other
See details
2007-05-29 Vivalis (France)/CSL (Australia)
 
EBx® cell lines / human influenza vaccines /   licensing
See details
2007-05-25 Vivalis (France)
GSK (GB)
EBx® cell lines / influenza vaccines /   other
See details
2007-05-24 Micromet (Germany-USA)
Nycomed (Denmark)
anti GM-CSF monoclonal antibodies, including MT203 / inflammatory diseases and autoimmune diseases R&D
commercialization/ distribution
See details
2007-05-23  
Organon (The Netherlands)/Royal Philips Electronics (The Netherlands)
  / cancer, CNS diseases R&D
See details
2007-05-22 EpiStem (GB)
AstraZeneca (GB)
biomarker technology /   R&D
See details
2007-05-18 Creabilis Therapeutics (Italy)
Bionucleon (Italy)
 
aptamers / inflammatory diseases, auto-immune diseases development
See details
2007-05-17 Siena Biotech (Italy)
Roche (Switzerland)
  / neurodegenerative diseases R&D
See details
2007-05-17 Vernalis (GB)
Servier (France)
  / cancer R&D
See details
2007-05-09 BT Pharma (France)
Ceva Santé Animale (France)
therapeutic vaccines / cancer R&D
development
See details
[<<]      «      50   |   51   |   52   |   53   |   54   |   55   |   56   |   57   |   58   |   59   |   60      »      [65]